Integrated Solutions

Medicilon is a Preclinical Research Outsourcing (CRO) company. With our more than 10 years experience on preclinical research services, we dedicated to provide our clients with customized preclinical services program in drug metabolism, pharmacokinetics, efficacy studies, and toxicology. We provide our clients a high-quality data and rapid turnaround time to support their drug development, preclinical studies and clinical research and to help them to select the most valuable drug candidates into clinical trials stage. Our preclinical research services consist in three major parts: pharmacokinetics, disease transplantation models and drug safety evaluation. Our preclinical research services cover all of the aspects including design, in vivo studies, sample analysis, professional data analysis, IACUC review, and the preparation of application materials.

Medicilon has constructed the GMP Drug Products Pilot Plant to meet the rising needs for innovative medicine R&D, production, packaging, inspections and stability tests. We are aiming for qualified CDMO services for clients with requirements for the development of innovative medicine.

Medicilon offers the one-stop shop integrated chemical drug R&D services including customized synthesis, medicinal chemistry, focused library preparation and process chemistry. Either in FTE or integrated project team arrangement, our chemistry team has helped clients discover novel and potent chemical series. Our contribution has led to numerous preclinical and clinical candidates. We also provide scale-up service to timely deliver kilograms of high-quality compounds.

The Medicilon Process Department is deeply involved in the entire industrial chain system of the R&D, procurement and production, from preclinical small-scale synthesis route optimization, process development and scale-up, process validation, quality research to commercial production.

Each ADC R&D project is its own challenge due to the varieties in the assembly of ADC molecules. With this concept in mind, Medicilon promises careful planning, meticulous execution and accurate results through years of practical experience and effective communication with our clients.

Medicilon gathers the popular POI ligands and multiple tissue types of E3 ligase ligands, in addition of established a linker library containing hundreds of linking molecules.

Medicilon has provided comprehensive support and services for the safety and effectiveness evaluation of various new drugs and vaccines， specifically the research of LNP-mRNA drugs and vaccines, accumulating rich experience. Hence we establish the bioanalysis platform for mRNA vaccines.

Medicilon has built a one-stop research platform for the preclinical R&D of cellular immunotherapies, covering a variety of immunotherapy methods including CAR-T, TCR-T and CAR-NK. Using a wealth of animal models and a variety of advanced analysis techniques, comprehensively considering the characteristics of different research projects, Medicilon has completed numerous pre-clinical projects for clients worldwide.

Medicilon nucleic acid drug R&D platform is an integrated and comprehensive solution that covers drug discovery, CMC and preclinical research services. Based on a rigorous scientific attitude, an open-minded scientific spirit and advanced equipment, our integrated solution can meet the industry's research and development needs for cutting-edge innovative nucleic acid drugs, and undertake research programs like nucleic acid drug discovery, screening and preclinical research services for pharmaceutical companies and scientific research institutions.

In recent years, tumor immunotherapy has become the core of cancer treatment research. With innovation as the driving force, Medicilon has vigorously developed a tumor immunity (Immuno-oncology) drug efficacy evaluation research platform. At present, CAR-T, TCR-T, CAR-NK, oncolytic virus, antibodies (monoclonal antibodies, bispecific antibodies, polyclonal antibodies, etc.), siRNA, AAV and other immunotherapy models and methods are used for evaluating the efficacy of immunotherapy and empowering the research process of innovative therapies and protect health!

The preclinical pharmacology department of Medicilon has been deeply involved in this field for many years, and has provided a variety of stable and reliable animal models for different targets and pathways for the evaluation of inflammatory immune disease treatments in order for the successful clinical transformation.

Cardiovascular and cerebrovascular diseases generally refer to ischemic or hemorrhagic diseases of the heart, brain and systemic tissues caused by hyperlipidemia, blood viscosity, atherosclerosis, and hypertension.

Medicilon is familiar with the development process and has extensive R&D experience of various inhalation formulations, especially in the field of DPI, nebulizer and nasal spray. The R&D are fully integrated with the requirements of domestic and foreign policies, regulations and guidelines.

With the help of the ophthalmic operating microscope, we can apply special methods of fine ophthalmic drug delivery for animal species such as rabbits, dogs, miniature pigs and non-human primates, in addition to conventional ways like eye drops and eye ointment administration, etc.

Medicilon can undertake the development process of various topical skin preparations, including ointments, creams, gels and other semi-solid preparations, as well as lotions, liniments and other solutions. Medicilon fully complies with the requirements of China and global laws and regulations and guiding principles, as well as many years of development and research experience. Medicilon has completed the development and application of a number of external preparation research projects for pharmaceutical companies and scientific research institutes.